Patents Assigned to IMTM GmbH
-
Patent number: 8470855Abstract: Compounds of the general formulae (1) and (2) A-B-D-B?-A???(1) and A-B-D-E??(2) in which A and A? may be identical or different and are the residue in which X is S, O, CH2, CH2CH2, CH2O or CH2NH, and Y is H or CN, and * designates a chiral carbon atom preferably in S- or L-configuration; B and B? may be identical or different and are an O, N or S containing or non-containing, unsubstituted or substituted, unbranched or branched alkylene residue, cycloalkylene residue, aralkylene residue, heterocycloalkylene residue, heteroarylalkylene residue, arylamidoalkylene residue, heteroarylamidoalkylene residue, unsubstituted or mono- or poly-substituted arylene residue or heteroarylene residue having one or more five-, six- or seven-membered ring(s); D is —S—S— or —Se—Se—; and E is the group —CH2—CH(NH2)—R9 or —CH2—*CH(NH2)—R9 respectively in which R9 is an O, N or S containing or non-containing, unsubstituted or substituted, unbranched or branched alkyl residue, cycloalkyl residue, aralkyl residuType: GrantFiled: November 10, 2006Date of Patent: June 25, 2013Assignee: IMTM GmbHInventors: Siegfried Ansorge, Klaus Neubert, Ute Bank, Irene Reichstein, Jürgen Faust, Michael Täger, Petra Fuchs, Bianca Senns
-
Publication number: 20120258960Abstract: The invention relates to compounds of the general formula (1) or the acid addition salts thereof with organic and/or inorganic acids; as well as to the use of the compounds of the general formula (1) in medicine.Type: ApplicationFiled: August 26, 2010Publication date: October 11, 2012Applicant: IMTM GMBHInventors: Siegfried Ansorge, Ute Bank, Karsten Nordhoff, Peter Roehnert, Sofia Stefin, Frank Striggow, Michael Taeger
-
Patent number: 8263636Abstract: The present invention relates to substances capable of specifically inhibiting Ala-p-nitroanilide-cleaving peptidases and Gly-Pro-p-nitroanilide-cleaving peptidases as well, for a use in the medical field. Furthermore, the invention relates to the use of at least one of such substances or of at least one pharmaceutical or cosmetic composition containing at least one such substance for a prophylaxis or a therapy of diseases, particularly for a prophylaxis and a therapy of diseases accompanied by an excessive immune response (autoimmune diseases, allergies, transplant rejections), of other chronic-inflammatory diseases, of neuronal diseases and cerebral damage, of skin diseases (inter alia acne, psoriasis), of tumor diseases and of specific virus infections (inter alia SARS).Type: GrantFiled: October 15, 2004Date of Patent: September 11, 2012Assignees: IMTM GmbH, Keyneurotek Pharmaceuticals AGInventors: Siegfried Ansorge, Ute Bank, Karsten Nordhoff, Michael Taeger, Frank Striggow
-
Publication number: 20120028995Abstract: The invention relates to compounds of general formula (I) as set forth in the claims as well as to the use of the compounds of the general formula (1) in the medical field, specifically for use in the suppression of DNA synthesis and inflammatory cytokine production as well as in the stimulation of anti-inflammatory cytokine production in vitro and in vivo. This abstract is neither intended to define the invention disclosed in this specification nor intended to limit the scope of the invention in any way.Type: ApplicationFiled: July 19, 2011Publication date: February 2, 2012Applicant: IMTM GMBHInventors: Siegfried ANSORGE, Ute BANK, Anke HEIMBURG, Heiko JULIUS, Karsten NORDHOFF, Michael TAEGER
-
Publication number: 20110117069Abstract: The invention relates to a method for activating regulatory t-cells (Treg-cells) of the human or animal body, comprising a step of bringing into contact the regulatory t-cells (Treg-cells) in a suitable liquid medium with one or a plurality of inhibitors of alanyl-amino peptidase (amino peptidase N; APN) and/or with one or a plurality of inhibitors of peptidases with the same substrate specificity to induce a suppressive effect of the regulatory t-cells (Treg-cells).Type: ApplicationFiled: August 21, 2008Publication date: May 19, 2011Applicant: IMTM GMBHInventors: Siegfried Ansorge, Ute Bank, Uwe Lendeckel, Janine Tadje, Michael Taeger, Carmen Wolke
-
Patent number: 7803776Abstract: Provided are combinations of inhibitors of dipeptidyl peptidase IV (DP IV) and of enzymes having the same substrate specificity (DP IV-analogous enzymatic activity) and inhibitors of alanyl aminopeptidase (aminopeptidase N, APN) and of enzymes having the same substrate specificity (APN-analogous enzymatic activity) and use of the same to obtain a more than additive to superadditive inhibition for the treatment of arteriosclerosis, for the treatment of allergic reactions of the type I according to the Gell and Coombs classification and for the treatment of dermatological diseases with follicular and epidermal hyperkeratoses and an enhanced proliferation of keratinocytes.Type: GrantFiled: June 11, 2007Date of Patent: September 28, 2010Assignee: Institut fur Medizintechnologie Magdeburg (IMTM) GmbHInventors: Siegfried Ansorge, Uwe Lendeckel, Klaus Neubert, Dirk Reinhold, Robert Vetter, Harald Gollnick
-
Patent number: 7683034Abstract: The invention relates to a process for the-inhibition of the DNA synthesis necessary for the proliferation of human sebaceous cells (sebocytes) by the isolated or joint effect of inhibitors of alanyl aminopeptidase (APN) and dipetidyl peptidase IV (DP IV) expressed by these cells. The DNA synthesis (proliferation) of human sebaceous cells is inhibited by the administration of the inhibitors of APN and/or of DP IV depending on the dose. Our invention shows that, for a therapy and for a prevention of dermatological diseases with sebaceous hyperproliferation and modified conditions of differentiation, the application of inhibitors of the above-mentioned enzymes and of corresponding pharmaceutical preparations and dosage forms thereof is suitable.Type: GrantFiled: March 7, 2003Date of Patent: March 23, 2010Assignee: IMTM GmbHInventors: Siegfried Ansorge, Harald Gollnick, Klaus Neubert, Christos Zouboulis, Jurgen Faust, Uwe Lendeckel, Dirk Reinhold, Robert Vetter
-
Publication number: 20090124667Abstract: Compounds of the general formulae (1) and (2) A-B-D-B?-A???(1) and A-B-D-E??(2) in which A and A? may be identical or different and are the residue in which X is S, O, CH2, CH2CH2, CH2O or CH2NH, and Y is H or CN, and * designates a chiral carbon atom preferably in S- or L-configuration; B and B? may be identical or different and are an O, N or S containing or non-containing, unsubstituted or substituted, unbranched or branched alkylene residue, cycloalkylene residue, aralkylene residue, heterocycloalkylene residue, heteroarylalkylene residue, arylamidoalkylene residue, heteroarylamidoalkylene residue, unsubstituted or mono- or poly-substituted arylene residue or heteroarylene residue having one or more five-, six- or seven-membered ring(s); D is —S—S— or —Se—Se—; and E is the group —CH2—CH(NH2)—R9 or —CH2—*CH(NH2)—R9 respectively in which R9 is an O, N or S containing or non-containing, unsubstituted or substituted, unbranched or branched alkyl residue, cycloalkyl residue, aralkyl residType: ApplicationFiled: November 10, 2006Publication date: May 14, 2009Applicant: IMTM GmbHInventors: Siegfried Ansorge, Klaus Neubert, Ute Bank, Irene Reichstein, Jurgen Faust, Michael Tager, Petra Fuchs, Bianca Senns
-
Patent number: 7485626Abstract: The invention comprises a process wherein the DNA synthesis and, thus, the proliferation of mononuclear cells (MNZ) and of T cells as well is inhibited by the simultaneous and combined inhibition of the enzyme activity (I) of alanyl aminopeptidase and of dipeptidyl peptidase IV; (II) of dipeptidyl peptidase IV and of the angiotensin-converting enzyme; (III) of dipeptidyl peptidase IV and of prolyl oligopeptidase; and (IV) of dipeptidyl peptidase IV and of X-Pro-aminopeptidase to an extent which cannot be achieved by an application of a single one of said enzyme inhibitors, even at a higher dosage. Although the said inhibitors exercise an influence on the very same process finally, i.e. the DNA synthesis and, thus, the proliferation of immune cells, this effect is not complete and is not long lasting when a single inhibitor is applied.Type: GrantFiled: May 22, 2001Date of Patent: February 3, 2009Assignee: IMTM GmbHInventors: Siegfried Ansorge, Marco Arndt, Frank Buehling, Uwe Lendeckel, Klaus Neubert, Dirk Reinhold, Stefan Brocke
-
Patent number: 7429614Abstract: The invention relates to a medicament containing an effector of the glutathione metabolism together with ?-lipoic acid for treating diabetes mellitus. This medicament enables disturbances of the thiol-disulfide status or those that occur, for example, in diabetes mellitus to be treated simultaneously, separately or in a temporally graduated manner.Type: GrantFiled: May 27, 2002Date of Patent: September 30, 2008Assignees: Esparma GmbH, IMTM GmbHInventors: Michael Taeger, Siegfried Ansorge, Gerhard Fries, Dieter Koegst
-
Patent number: 7425532Abstract: The present invention relates to the use of one inhibitor or of several inhibitors of alanyl aminopeptidases and/or of enzymes having a similar substrate specificity for the induction of the production of TGF-?1 and of the expression of TGF-?1 in and/or on Treg cells and relates to the use for preventing and/or treating autoimmune diseases, allergies, arteriosclerosis and for suppressing graft rejection reactions. The invention furthermore relates to uses, wherein peptide fragments of pathogenic autoantigens or synthetic analogs and/or specific antigenic components of pathogenic microorganisms are used in addition.Type: GrantFiled: July 4, 2003Date of Patent: September 16, 2008Assignee: IMTM GmbHInventors: Siegfried Ansorge, Janine Tadje, Uwe Lendeckel
-
Publication number: 20070212339Abstract: The present invention relates to the use of at least one effector of glutathione metabolism together with ?-lipoic acid, its salts and/or its pro-drugs for the simultaneous, separate or timed cytoprotective treatment of chronically obstructive lung diseases.Type: ApplicationFiled: December 23, 2004Publication date: September 13, 2007Applicants: ESPARMA GMBH, IMTM GMBHInventors: Siegfried Ansorge, Dieter Koegst, Michael Taeger, Gerhard Fries
-
Patent number: 7229969Abstract: Combination of inhibitors of dipeptidyl peptidase IV (DP IV) and enzymes having the same substrate specificity (DP IV-analogous enzymatic activity) and inhibitors of alanyl aminopeptidase (aminopeptidase N, APN) and of enzymes having the same substrate specificity (APN-analogous enzymatic activity) for a more than additive to superadditive inhibition for the treatment of arteriosclerosis, for the treatment of allergic reactions of the type I according to the Gell and Coombs classification and for the treatment of dermatological diseases with follicular and epidermal hyperkeratoses and an enhanced proliferation of keratinocytes.Type: GrantFiled: December 21, 2001Date of Patent: June 12, 2007Assignee: IMTM GmbHInventors: Siegfried Ansorge, Uwe Lendeckel, Klaus Neubert, Dirk Reinhold, Robert Vetter, Harald Gollnick